Patents by Inventor Mark Rogers-Evans

Mark Rogers-Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazine derivatives as CB2 receptor agonists
    Patent number: 9512141
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 receptor agonist for use in the treatment of several disorders, such as pain, atherosclerosis and glaucoma.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: December 6, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Baledi Dhurwasulu, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Pyrazole compounds as CB2 agonists
    Patent number: 9512132
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 6, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Nettekoven Matthias, Ricklin Fabienne, Roever Stephan, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Purine derivatives as CB2 receptor agonists
    Patent number: 9505762
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: November 29, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Pyridine-2-amides useful as CB2 agonists
    Patent number: 9409866
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: August 9, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch, Matthias Westphal
  • Pyrazine derivatives
    Patent number: 9403808
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. In particular, the compound may be used as a preferential agonist of Cannabinoid Receptor 2.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: August 2, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Baledi Dhurwasulu, Uwe Grether, Anindya Hazra, Paul Hebeisen, Stephan Roever, Mark Rogers-Evans
  • NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
    Publication number: 20160168158
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Mark Rogers-Evans, Stephan Roever, Sebastien Schmitt, Atsushi Kimbara
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160137606
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • Pyridine derivatives as agonists of the CB2 receptor
    Patent number: 9321727
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: April 26, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE
    Publication number: 20160101102
    Abstract: The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is —NR2R3; R2 is hydrogen or lower alkyl; R3 is lower alkyl; tetrahydropyran-4-yl; —CH2-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is —CH2— or —(CH2)2—; Ar is phenyl or pyridinyl; R4 is halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a ste
    Type: Application
    Filed: October 15, 2015
    Publication date: April 14, 2016
    Applicant: REMYND NV
    Inventors: Gerard Griffioen, Giuseppe Cecere, Matthias Nettekoven, Katrien Princen, Hasane Ratni, Mark Rogers-Evans, Walter Vifian
  • BACE1 INHIBITORS
    Publication number: 20160102105
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: October 7, 2015
    Publication date: April 14, 2016
    Inventors: Bjoern Bartels, Philipp Cueni, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Walter Vifian, Thomas Woltering
  • Pyridine-2-amides useful as CB2 agonists
    Patent number: 9303012
    Abstract: The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: April 5, 2016
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Ernst Schaffter, Tanja Schulz-Gasch
  • NOVEL TETRAZOLONE DERIVATIVES
    Publication number: 20160083357
    Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 24, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Pyridine derivatives as agonists of the CB2 receptor
    Patent number: 9290451
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20160046631
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20160046637
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160016968
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 28, 2015
    Publication date: January 21, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Olivier GAVELLE, Uwe GRETHER, Atsushi KIMBARA, Nettekoven MATTHIAS, Roever STEPHAN, Mark ROGERS-EVANS, Didier ROMBACH, Tanja SCHULZ-GASCH
  • NOVEL PYRAZOL DERIVATIVES
    Publication number: 20150376192
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 31, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, NETTEKOVEN MATTHIAS, RICKLIN FABIENNE, ROEVER STEPHAN, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS
    Publication number: 20150344429
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Application
    Filed: December 4, 2013
    Publication date: December 3, 2015
    Inventors: Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Fabienne RICKLIN, Stephan ROEVER, Mark ROGERS-EVANS, Didier ROMBACH, Tanja SCHULZ-GASCH, Matthias WESTPHAL
  • Substituted pyridazines as PDE10A inhibitors
    Patent number: 9187455
    Abstract: The present invention is concerned with novel pyridazinone derivatives of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as pharmaceuticals.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: November 17, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Daniela Alberati, Matthias Koerner, Bernd Kuhn, Jens-Uwe Peters, Rosa Maria Rodriguez Sarmiento, Mark Rogers-Evans, Markus Rudolph
  • Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
    Patent number: 9187440
    Abstract: The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is —NR2R3; R2 is hydrogen or lower alkyl; R3 is lower alkyl; tetrahydropyran-4-yl; —CH2-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is —CH2—or —(CH2)2—; Ar is phenyl or pyridinyl; R4 is halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a ster
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: November 17, 2015
    Assignee: REMYND NV
    Inventors: Gerard Griffioen, Giuseppe Cecere, Matthias Nettekoven, Katrien Princen, Hasane Ratni, Mark Rogers-Evans, Walter Vifian